Kestra Medical Technologies, Ltd.
HealthcareNASDAQ:KMTS · NASDAQ Global Select
+$0.71 today
Vol 0.33M · Avg 0.36M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-55.4%
avg -526.8%
ROIC
-41.2%
avg -369.4%
ROA
-38.5%
avg -189.4%
Analysis
ROA is currently the strongest return metric at -38.5% versus its period average of -189.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brian Webster | Founder, President, Chief Executive Officer & Director | $1.00M | — | 62 | $410,467.00 | 0.70% |
Vaseem Mahboob | Chief Financial Officer | $674,252.00 | — | 57 | $67,961.00 | 0.12% |
Traci S. Umberger | Co-Founder, General Counsel, Chief Administrative Officer, Secretary & Director | $630,539.00 | — | 63 | $161,860.00 | 0.28% |
Gordon Teddy | Chief Information Officer | — | — | — | — | — |
Jeffrey Laub | Senior Vice President of Operations | — | — | 55 | $10,909.00 | 0.02% |
Neil Bhalodkar | Vice President of Investor Relations | — | — | — | — | — |
Timothy Moran | Chief Business Officer | — | — | 54 | $42,261.00 | 0.07% |
Debra Schotz | Senior Vice President of Marketing | — | — | 56 | — | — |
Alfred J. Ford Jr. | Chief Commercial Officer | — | — | 55 | $74,639.00 | 0.13% |
Phillip D. Foshee Jr. | Senior Vice President of Research & Development | — | — | 69 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$199,800.00
Sells
10
$2.32M
Net Sentiment
$2.12M
Net selling
Most Active
Webster Brian Daniel
9 transactions
1–10 of 11
Analysis
Insiders reported 1 buys worth $199,800.00 and 10 sells worth $2.32M over the last 12 months. That adds up to net selling of $2.12M. Webster Brian Daniel was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +45.6% (4yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +45.6% (4yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Terns Pharmaceuticals, Inc.
TERN
$4.77B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Neogen Corporation
NASDAQ:NEOG
$1.98B
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.69B
STAAR Surgical Company
NASDAQ:STAA
$1.41B
Precigen, Inc.
NASDAQ:PGEN
$1.34B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.28B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Evotec SE
NASDAQ:EVO
$966.11M
Who manages KMTS?
Kestra Medical Technologies, Ltd. (KMTS) lists 10 active executives. The top listed executive is Gordon Teddy, Chief Information Officer.
Are KMTS insiders buying or selling?
Recent insider activity shows net selling of $1.27M.
Explore More
Continue the stock analysis
Jump to another research area for this company.